HCW Biologics Inc. (HCWB)
HCW Biologics Inc. (HCWB) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 4.02M |
| Revenue (ttm) | 6.59M |
| Net Income (ttm) | -18.12M |
| Beta | 2.36 |
| EPS (ttm) | -49.74 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.58 |
| P/B (ttm) | 0.49 |
| P/S (ttm) | 0.61 |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 58,816 |
| Avg. Volume (20D) | 898,272 |
| Open | 2.65 |
| Previous Close | 2.68 |
| Day's Range | 2.47 - 2.90 |
| 52-Week Range | 1.50 - 44.10 |
| Analyst | n/a |
| Price Target | 30 (1090.48%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which ...
Financial Performance
In 2025, HCW Biologics's revenue was 54.23K, a decrease of -97.89% compared to the previous year's 2.57M. Earnings were -7.96M, a decrease of -73.49%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for HCWB stock is "null". The 12-month stock price forecast is 30, which is upside of 1090.48% from the latest price.
Stock ForecastsEarnings Surprise
5 months ago · Associated Press Finance
BC-Most Active StocksYY Group Holdings Ltd. 26,117,734 0.0511